Clinically, GLP-1 RAs were initially approved for type 2 diabetes mellitus (T2DM) management, demonstrating durable glycemic control and cardiovascular risk reduction in trials ( [3] )
This is one of the more researched uses of IV nutrient therapy, but trial data remains small and mixed
Reduces hepatic fat accumulation, aiding NAFLD
this has been observed in many proteins [49, 50]
Ferulic Acid + Tocopherol: Antioxidants that enhance brightening efficacy
Third, we included a small amount of non-metabolisable glucose analogue, 3- O -methylglucose, in the glucose solution with the intention of measuring serum 3- O -methylglucose concentrations as an index of small intestinal glucose absorption